Literature DB >> 26401003

Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules.

Celia R Berkers1, Annemieke de Jong1, Karianne G Schuurman1, Carsten Linnemann2, Hugo D Meiring3, Lennert Janssen1, Jacques J Neefjes1, Ton N M Schumacher2, Boris Rodenko1, Huib Ovaa4.   

Abstract

Peptide splicing, in which two distant parts of a protein are excised and then ligated to form a novel peptide, can generate unique MHC class I-restricted responses. Because these peptides are not genetically encoded and the rules behind proteasomal splicing are unknown, it is difficult to predict these spliced Ags. In the current study, small libraries of short peptides were used to identify amino acid sequences that affect the efficiency of this transpeptidation process. We observed that splicing does not occur at random, neither in terms of the amino acid sequences nor through random splicing of peptides from different sources. In contrast, splicing followed distinct rules that we deduced and validated both in vitro and in cells. Peptide ligation was quantified using a model peptide and demonstrated to occur with up to 30% ligation efficiency in vitro, provided that optimal structural requirements for ligation were met by both ligating partners. In addition, many splicing products could be formed from a single protein. Our splicing rules will facilitate prediction and detection of new spliced Ags to expand the peptidome presented by MHC class I Ags.
Copyright © 2015 by The American Association of Immunologists, Inc.

Mesh:

Substances:

Year:  2015        PMID: 26401003      PMCID: PMC4642839          DOI: 10.4049/jimmunol.1402455

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

Review 1.  SYFPEITHI: database for MHC ligands and peptide motifs.

Authors:  H Rammensee; J Bachmann; N P Emmerich; O A Bachor; S Stevanović
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

2.  Design and use of conditional MHC class I ligands.

Authors:  Mireille Toebes; Miriam Coccoris; Adriaan Bins; Boris Rodenko; Raquel Gomez; Nella J Nieuwkoop; Willeke van de Kasteele; Guus F Rimmelzwaan; John B A G Haanen; Huib Ovaa; Ton N M Schumacher
Journal:  Nat Med       Date:  2006-02-05       Impact factor: 53.440

3.  Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7.

Authors:  Arnold H Bakker; Rieuwert Hoppes; Carsten Linnemann; Mireille Toebes; Boris Rodenko; Celia R Berkers; Sine Reker Hadrup; Wim J E van Esch; Mirjam H M Heemskerk; Huib Ovaa; Ton N M Schumacher
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

Review 4.  Diversity of proteasomal missions: fine tuning of the immune response.

Authors:  Ljudmila Borissenko; Michael Groll
Journal:  Biol Chem       Date:  2007-09       Impact factor: 3.915

Review 5.  Transpeptidation and reverse proteolysis and their consequences for immunity.

Authors:  Celia R Berkers; Annemieke de Jong; Huib Ovaa; Boris Rodenko
Journal:  Int J Biochem Cell Biol       Date:  2008-09-04       Impact factor: 5.085

6.  Targeted identification of infection-related HLA class I-presented epitopes by stable isotope tagging of epitopes (SITE).

Authors:  H D Meiring; E C Soethout; A P J M de Jong; C A C M van Els
Journal:  Curr Protoc Immunol       Date:  2007-05

7.  Fluorescence-based proteasome activity profiling.

Authors:  Annemieke de Jong; Karianne G Schuurman; Boris Rodenko; Huib Ovaa; Celia R Berkers
Journal:  Methods Mol Biol       Date:  2012

8.  Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding.

Authors:  Michael Groll; Robert Huber; Barbara C M Potts
Journal:  J Am Chem Soc       Date:  2006-04-19       Impact factor: 15.419

9.  Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.

Authors:  Gavin M Bendle; Carsten Linnemann; Anna I Hooijkaas; Laura Bies; Moniek A de Witte; Annelies Jorritsma; Andrew D M Kaiser; Nadine Pouw; Reno Debets; Elisa Kieback; Wolfgang Uckert; Ji-Ying Song; John B A G Haanen; Ton N M Schumacher
Journal:  Nat Med       Date:  2010-04-18       Impact factor: 53.440

10.  Immune recognition of a human renal cancer antigen through post-translational protein splicing.

Authors:  Ken-Ichi Hanada; Jonathan W Yewdell; James C Yang
Journal:  Nature       Date:  2004-01-15       Impact factor: 49.962

View more
  24 in total

Review 1.  HIPs and HIP-reactive T cells.

Authors:  T A Wiles; T Delong
Journal:  Clin Exp Immunol       Date:  2019-06-17       Impact factor: 4.330

2.  Peptide Splicing in the Proteasome Creates a Novel Type of Antigen with an Isopeptide Linkage.

Authors:  Celia R Berkers; Annemieke de Jong; Karianne G Schuurman; Carsten Linnemann; Jan A J Geenevasen; Ton N M Schumacher; Boris Rodenko; Huib Ovaa
Journal:  J Immunol       Date:  2015-09-23       Impact factor: 5.422

Review 3.  Peptide splicing by the proteasome.

Authors:  Nathalie Vigneron; Violette Ferrari; Vincent Stroobant; Joanna Abi Habib; Benoit J Van den Eynde
Journal:  J Biol Chem       Date:  2017-11-06       Impact factor: 5.157

4.  Proteasome Levels and Activity in Pregnancies Complicated by Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Thrombocytopenia (HELLP) Syndrome.

Authors:  Kathryn Berryman; Catalin S Buhimschi; Guomao Zhao; Michelle Axe; Megan Locke; Irina A Buhimschi
Journal:  Hypertension       Date:  2019-06       Impact factor: 10.190

Review 5.  Current tools for predicting cancer-specific T cell immunity.

Authors:  David Gfeller; Michal Bassani-Sternberg; Julien Schmidt; Immanuel F Luescher
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

Review 6.  Present Yourself! By MHC Class I and MHC Class II Molecules.

Authors:  Kenneth L Rock; Eric Reits; Jacques Neefjes
Journal:  Trends Immunol       Date:  2016-09-07       Impact factor: 16.687

7.  Global Identification of Post-Translationally Spliced Peptides with Neo-Fusion.

Authors:  Zach Rolfs; Stefan K Solntsev; Michael R Shortreed; Brian L Frey; Lloyd M Smith
Journal:  J Proteome Res       Date:  2018-10-31       Impact factor: 4.466

Review 8.  Spliced HLA-bound peptides: a Black Swan event in immunology.

Authors:  P Faridi; M Dorvash; A W Purcell
Journal:  Clin Exp Immunol       Date:  2021-03-28       Impact factor: 4.330

9.  Database search engines and target database features impinge upon the identification of post-translationally cis-spliced peptides in HLA class I immunopeptidomes.

Authors:  Michele Mishto; Yehor Horokhovskyi; John A Cormican; Xiaoping Yang; Steven Lynham; Henning Urlaub; Juliane Liepe
Journal:  Proteomics       Date:  2022-03-03       Impact factor: 5.393

10.  Response: Commentary: An In Silico-In Vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients.

Authors:  Michele Mishto; Guillermo Rodriguez-Hernandez; Jacques Neefjes; Henning Urlaub; Juliane Liepe
Journal:  Front Immunol       Date:  2021-07-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.